466 related articles for article (PubMed ID: 27342548)
21. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
Marin AC; McNicholl AG; Gisbert JP
Expert Opin Pharmacother; 2013 May; 14(7):843-61. PubMed ID: 23537368
[TBL] [Abstract][Full Text] [Related]
22. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Helicobacter; 2016 Oct; 21(5):382-8. PubMed ID: 26809022
[TBL] [Abstract][Full Text] [Related]
23. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
[TBL] [Abstract][Full Text] [Related]
24. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
[TBL] [Abstract][Full Text] [Related]
25. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
[TBL] [Abstract][Full Text] [Related]
26. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
27. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
29. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
[TBL] [Abstract][Full Text] [Related]
30. [What is currently the Helicobacter pylori eradication therapy of choice? Triple therapy (PPI, amoxicillin and clarithromycin) or sequential therapy (PPI and amoxicillin for 5 days followed by PPI, clarithromycin and metronidazole for a further 5 days)?].
Sánchez-Delgado J
Gastroenterol Hepatol; 2009 Jan; 32(1):68-9. PubMed ID: 19174106
[No Abstract] [Full Text] [Related]
31. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.
Gisbert JP; Calvet X
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1255-68. PubMed ID: 22017749
[TBL] [Abstract][Full Text] [Related]
32. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
[TBL] [Abstract][Full Text] [Related]
34. Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry.
Le Thi TG; Werkstetter K; Kotilea K; Bontems P; Cabral J; Cilleruelo Pascual ML; Kori M; Barrio J; Homan M; Kalach N; Lima R; Tavares M; Urruzuno P; Misak Z; Urbonas V; Koletzko S;
Infection; 2023 Aug; 51(4):921-934. PubMed ID: 36329342
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
[TBL] [Abstract][Full Text] [Related]
37. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection.
Chen MJ; Chen CC; Chen YN; Chen CC; Fang YJ; Lin JT; Wu MS; Liou JM;
Am J Gastroenterol; 2018 Oct; 113(10):1444-1457. PubMed ID: 30171216
[TBL] [Abstract][Full Text] [Related]
38. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
39. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
Liou JM; Chen CC; Chang CY; Chen MJ; Chen CC; Fang YJ; Lee JY; Yang TH; Luo JC; Wu JY; Liou TC; Chang WH; Hsu YC; Tseng CH; Chang CC; Bair MJ; Liu TY; Hsieh CF; Tsao FY; Shun CT; Lin JT; Lee YC; Wu MS;
Gut; 2016 Nov; 65(11):1784-1792. PubMed ID: 26338825
[TBL] [Abstract][Full Text] [Related]
40. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
